| Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis. | |
| | |
MedLine Citation:
|
PMID: 11603629 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We aimed to further assess the safety and efficacy of low-dose oral methotrexate (LDOM) treatment for chronic progressive MS (CPMS). We studied 20 CPMS patients, including 16 with secondary progressive MS who had shown disease progression in the previous year. The mean follow-up was 23 months. The mean EDSS score was 6.3+/-1.1 before treatment and 6.4+/-1.1 after one year of treatment. At one year, 15 of 20 patients were still being treated, and 10 were stable. Twelve patients have completed 18 months of treatment, and eight are stable. Two patients stopped treatment because of side effects, two more because they did not perceive benefit, and one was lost to follow-up. Six patients had mild, transient increases in liver enzymes not requiring treatment interruption, and two had localized herpes zoster. Magnetic resonance imaging (MRI) performed before treatment and at one year remained unchanged in responders. We confirm that LDOM is safe in carefully selected and monitored CPMS patients. MTX is inexpensive and, given its anti-inflammatory and immunomodulatory properties, may be used as add-on therapy in non-responders to interferon beta, although hepatic toxicity may be a problem in long-term treatment. |
| | |
Authors:
|
A Lugaresi; C Caporale; D Farina; F Marzoli; L Bonanni; P A Muraro; G De Luca; C Iarlori; D Gambi |
Related Documents
:
|
17762459 - Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during tr... 3915889 - Rectal administration of tenoxicam for the treatment of rheumatoid arthritis and arthro... 1445449 - The treatment of wegener's granulomatosis with glucocorticoids and methotrexate. 23332899 - Effect of stentboost imaging guided percutaneous coronary intervention on mid-term angi... 22926459 - Reducing waiting time for community rehabilitation services: a controlled before and af... 12382299 - Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic... 17764879 - A randomized trial of the tubulcus multilayer bandaging system in the treatment of exte... 15714369 - Tibial angioplasty as an alternative strategy in patients with limb-threatening ischemia. 8496229 - Simultaneous multiple operations for spastic diplegia. outcome and functional assessmen... |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology Volume: 22 ISSN: 1590-1874 ISO Abbreviation: Neurol. Sci. Publication Date: 2001 Apr |
Date Detail:
|
Created Date: 2001-10-17 Completed Date: 2002-04-17 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 100959175 Medline TA: Neurol Sci Country: Italy |
Other Details:
|
Languages: eng Pagination: 209-10 Citation Subset: IM |
Affiliation:
|
Department of Oncology and Neuroscience, Gabriele d'Annunzio University, Chieti, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Dose-Response Relationship, Drug Humans Immunosuppressive Agents / administration & dosage*, adverse effects Magnetic Resonance Imaging Methotrexate / administration & dosage*, adverse effects Middle Aged Multiple Sclerosis, Chronic Progressive / drug therapy*, pathology, physiopathology Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Immunosuppressive Agents; 59-05-2/Methotrexate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: To treat or not to treat the person with clinical multiple sclerosis--a dilemma.
Next Document: International connections among midwives.